AnaptysBio, Inc.
ANAB
$59.43
-$0.56-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 80.95% | 90.89% | 48.91% | 22.06% | 13.89% |
| Total Depreciation and Amortization | 1.21% | 1.08% | 0.75% | 0.33% | 0.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.54% | 50.67% | 76.41% | 99.62% | 98.66% |
| Change in Net Operating Assets | -62.76% | -21.71% | -81,735.75% | -815.47% | -257.03% |
| Cash from Operations | 104.12% | 114.55% | -40.73% | 1.31% | 18.50% |
| Capital Expenditure | 81.15% | 75.70% | 6.93% | 25.90% | 44.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 491.11% | 138.23% | -28.03% | -44.81% | -67.35% |
| Cash from Investing | 496.14% | 139.03% | -28.07% | -44.88% | -67.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -72.10% | -85.86% | -97.41% | 4,451.26% | 4,871.31% |
| Repurchase of Common Stock | -1,215.61% | -14,949.56% | -- | -- | 60.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -499.88% | -393.42% | 118.99% | -240.79% | 166.89% |
| Cash from Financing | -191.72% | -204.38% | -165.63% | -1.58% | 417.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 233.39% | 32.14% | -149.46% | -175.17% | 209.97% |